CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

A. Santoro, S. Viviani, P. Valagussa, V. Bonfante, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

Starting in February 1980, 58 patients with Hodgkin's disease refractory to both MOPP and ABVD received as third-line chemotherapy a combination of CCNU or lomustine, etoposide, and prednimustine (CEP). Complete response (CR) was achieved in 40% of cases and partial response (PR) in 14%. The median duration of CR was greater than 15 months, and the median survival of complete responders was longer than 24 months. In addition, CEP alternating with ABVD was given to 21 patients refractory to MOPP chemotherapy. In this series, CR was documented in 67% of patients with a median duration of 24+ months and a median survival of 36+ months. Treatment was generally well tolerated, and all acute side effects were reversible. Present findings indicate that CEP is an effective regimen in patients refractory to MOPP and ABVD.

Original languageEnglish
Pages (from-to)23-26
Number of pages4
JournalSeminars in Oncology
Volume13
Issue number1 SUPPL. 1
Publication statusPublished - 1986

Fingerprint

Prednimustine
Lomustine
Etoposide
Hodgkin Disease
Survival
Combination Drug Therapy
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Santoro, A., Viviani, S., Valagussa, P., Bonfante, V., & Bonadonna, G. (1986). CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Seminars in Oncology, 13(1 SUPPL. 1), 23-26.

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. / Santoro, A.; Viviani, S.; Valagussa, P.; Bonfante, V.; Bonadonna, G.

In: Seminars in Oncology, Vol. 13, No. 1 SUPPL. 1, 1986, p. 23-26.

Research output: Contribution to journalArticle

Santoro, A, Viviani, S, Valagussa, P, Bonfante, V & Bonadonna, G 1986, 'CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease', Seminars in Oncology, vol. 13, no. 1 SUPPL. 1, pp. 23-26.
Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Seminars in Oncology. 1986;13(1 SUPPL. 1):23-26.
Santoro, A. ; Viviani, S. ; Valagussa, P. ; Bonfante, V. ; Bonadonna, G. / CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. In: Seminars in Oncology. 1986 ; Vol. 13, No. 1 SUPPL. 1. pp. 23-26.
@article{4af3ca3687fa4bdb96c4454a21ea374f,
title = "CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease",
abstract = "Starting in February 1980, 58 patients with Hodgkin's disease refractory to both MOPP and ABVD received as third-line chemotherapy a combination of CCNU or lomustine, etoposide, and prednimustine (CEP). Complete response (CR) was achieved in 40{\%} of cases and partial response (PR) in 14{\%}. The median duration of CR was greater than 15 months, and the median survival of complete responders was longer than 24 months. In addition, CEP alternating with ABVD was given to 21 patients refractory to MOPP chemotherapy. In this series, CR was documented in 67{\%} of patients with a median duration of 24+ months and a median survival of 36+ months. Treatment was generally well tolerated, and all acute side effects were reversible. Present findings indicate that CEP is an effective regimen in patients refractory to MOPP and ABVD.",
author = "A. Santoro and S. Viviani and P. Valagussa and V. Bonfante and G. Bonadonna",
year = "1986",
language = "English",
volume = "13",
pages = "23--26",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

AU - Santoro, A.

AU - Viviani, S.

AU - Valagussa, P.

AU - Bonfante, V.

AU - Bonadonna, G.

PY - 1986

Y1 - 1986

N2 - Starting in February 1980, 58 patients with Hodgkin's disease refractory to both MOPP and ABVD received as third-line chemotherapy a combination of CCNU or lomustine, etoposide, and prednimustine (CEP). Complete response (CR) was achieved in 40% of cases and partial response (PR) in 14%. The median duration of CR was greater than 15 months, and the median survival of complete responders was longer than 24 months. In addition, CEP alternating with ABVD was given to 21 patients refractory to MOPP chemotherapy. In this series, CR was documented in 67% of patients with a median duration of 24+ months and a median survival of 36+ months. Treatment was generally well tolerated, and all acute side effects were reversible. Present findings indicate that CEP is an effective regimen in patients refractory to MOPP and ABVD.

AB - Starting in February 1980, 58 patients with Hodgkin's disease refractory to both MOPP and ABVD received as third-line chemotherapy a combination of CCNU or lomustine, etoposide, and prednimustine (CEP). Complete response (CR) was achieved in 40% of cases and partial response (PR) in 14%. The median duration of CR was greater than 15 months, and the median survival of complete responders was longer than 24 months. In addition, CEP alternating with ABVD was given to 21 patients refractory to MOPP chemotherapy. In this series, CR was documented in 67% of patients with a median duration of 24+ months and a median survival of 36+ months. Treatment was generally well tolerated, and all acute side effects were reversible. Present findings indicate that CEP is an effective regimen in patients refractory to MOPP and ABVD.

UR - http://www.scopus.com/inward/record.url?scp=0022982371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022982371&partnerID=8YFLogxK

M3 - Article

C2 - 2420012

AN - SCOPUS:0022982371

VL - 13

SP - 23

EP - 26

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -